KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Capital Expenditures (2016 - 2025)

Novavax has reported Capital Expenditures over the past 16 years, most recently at -$250000.0 for Q4 2025.

  • Quarterly results put Capital Expenditures at -$250000.0 for Q4 2025, down 102.18% from a year ago — trailing twelve months through Sep 2025 was $11.7 million (up 533.8% YoY), and the annual figure for FY2024 was $13.1 million, up 159.32%.
  • Capital Expenditures for Q4 2025 was -$250000.0 at Novavax, up from -$1.2 million in the prior quarter.
  • Over the last five years, Capital Expenditures for NVAX hit a ceiling of $19.8 million in Q1 2023 and a floor of -$16.8 million in Q2 2022.
  • Median Capital Expenditures over the past 5 years was $243000.0 (2023), compared with a mean of $1.6 million.
  • Biggest five-year swings in Capital Expenditures: skyrocketed 11195.9% in 2021 and later tumbled 513.19% in 2022.
  • Novavax's Capital Expenditures stood at $10.3 million in 2021, then tumbled by 177.92% to -$8.1 million in 2022, then soared by 102.97% to $239000.0 in 2023, then surged by 4690.79% to $11.4 million in 2024, then plummeted by 102.18% to -$250000.0 in 2025.
  • The last three reported values for Capital Expenditures were -$250000.0 (Q4 2025), -$1.2 million (Q3 2025), and $247000.0 (Q2 2025) per Business Quant data.